Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer

• US 20030148314A1
• Filed: 08/01/2002
• Published: 08/07/2003
• Est. Priority Date: 08/01/2001
• Status: Abandoned Application

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Guillemette, Tracy L., Morrissey, Michael P., Schlegel, Robert, Berger, Allison, Bryant, Barbara Moore
• Application Number:
  US10/210,314
• Publication Number:
  US 20030148314A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57419 of colon

Abstract

The invention relates to newly discovered nucleic acid molecules and proteins associated with colon cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided.

Claims

1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:

1-29.

2. A vector which contains the nucleic acid molecule of claim 1.

3. A host cell which contains the nucleic acid molecule of claim 1.

4. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:

1-29.

5. An antibody which selectively binds to the polypeptide of claim 4.

6. A method of assessing whether a patient is afflicted with colon cancer, the method comprising comparing:

a) the level of expression of a marker in a patient sample, wherein the marker is selected from the group consisting of n1-n333; and

b) the normal level of expression of the marker in a control non-colon cancer sample,

wherein a significant increase in the level of expression of the marker in the patient sample and the normal level is an indication that the patient is afflicted with colon cancer.